var data={"title":"Haloperidol: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Haloperidol: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6304?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=haloperidol-patient-drug-information\" class=\"drug drug_patient\">see &quot;Haloperidol: Patient drug information&quot;</a> and <a href=\"topic.htm?path=haloperidol-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Haloperidol: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6697563\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Increased mortality in elderly patients with dementia-related psychosis:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of 17 placebo-controlled trials (modal duration, 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was approximately 4.5%, compared with a rate of approximately 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be cardiovascular (eg, heart failure, sudden death) or infectious (eg, pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. Haloperidol is not approved for the treatment of patients with dementia-related psychosis.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178552\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Haldol;</li>\n      <li>Haldol Decanoate</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178553\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Novo-Peridol</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178603\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        First Generation (Typical) Antipsychotic</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178557\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Psychosis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Manufacturer's labeling: Oral: 0.5 to 5 mg 2 to 3 times daily; adjust dose based on response and tolerability. According to the manufacturer, daily dosages up to 100 mg may be necessary in some cases to achieve an optimal response; infrequently, doses &gt;100 mg have been used in severely treatment resistant patients. Recommended dose range for schizophrenia: 5 to 20 mg/day (APA [Lehman 2004)].</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Schizophrenia:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM (as lactate): 2 to 5 mg; subsequent doses may be administered as often as every 60 minutes, although 4- to 8-hour intervals may be satisfactory.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM (as decanoate): <b>Note:</b> Establish tolerance to oral haloperidol prior to changing to IM decanoate injection.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Initial: 10 to 20 times the daily oral dose. The initial dose should not exceed 100 mg regardless of previous antipsychotic requirements. If the initial dose conversion requires &gt;100 mg, administer the dose in 2 injections (maximum of 100 mg for first injection) separated by 3 to 7 days.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral haloperidol &le;10 mg/day, elderly, or debilitated: Initiate dose at 10 to 15 times the daily oral dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral haloperidol &gt;10 mg/day or high risk of relapse: Initiate dose at 20 times the daily oral dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance dose: 10 to 15 times the previous daily oral dose or 50 to 200 mg administer doses at 4-week intervals (Buchanan 2009; Hasan 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral overlap: Following initial dose, taper the oral dose and discontinue following the subsequent 2 or 3 injections (ie, 60 to 90 days) (McEvoy 2006). Alter rate of taper based on clinical response and presence of adverse events.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternative dosing regimen:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Loading dose regimen: Initial: 20 times the previous daily oral dose, divide total dose and give every 3 to 7 days, do not exceed 250 mg per injection; discontinue oral haloperidol prior to first injection. Reduce the dose by 25% each month, depending on clinical response, in months 2 to 4, and establish the maintenance dose.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Usual maintenance dose: 200 mg per month (Ereshefsky 1993)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Tourette syndrome:</b> Oral: 0.5 to 5 mg 2 to 3 times daily; adjust dose based on response and tolerability. Tourette Canada Guidelines recommend a dosing range of 0.5 to 3 mg/day (Pringsheim 2012) and European Society for the Study of Tourette Syndrome recommend a dosing range of 0.25 to 15 mg/day (Roessner 2011). According to the manufacturer, daily dosages up to 100 mg may be necessary in some cases to achieve an optimal response; infrequently doses &gt;100 mg have been used in severely treatment resistant patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chemotherapy-induced nausea and vomiting (off-label use):</b> Breakthrough nausea/vomiting: Oral, IV (off-label route): 0.5 to 1 mg every 6 hours as needed (Lohr 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chorea of Huntington disease (off-label use):</b> Oral: Initial: 0.5 to 2 mg/day; adjust dose based on response and tolerability up to a maximum dose of 10 mg/day (Reilmann 2013). Additional data may be necessary to further define the role of haloperidol in this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Delirium in the intensive care unit, treatment (off-label use):</b> <b>Note:</b> The optimal dose and regimen of haloperidol for the treatment of severe agitation and/or delirium has not been established. Currently, there are no studies evaluating the role of haloperidol on duration or severity of delirium. Haloperidol has been used for symptomatic treatment (severe agitation) of delirious patients. Current guidelines do not advocate use of haloperidol for the treatment or prevention of delirium due to insufficient evidence (Barr 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV (off-label route): Initial: 0.5 to 10 mg depending on degree of agitation; if inadequate response, may repeat bolus dose (with sequential doubling of initial bolus dose) every 15 to 30 minutes until calm achieved, then administer 25% of the last bolus dose every 6 hours; monitor ECG and QTc interval. After the patient is controlled, haloperidol therapy should be tapered over several days. This strategy is based upon expert opinion; efficacy and safety have not been formally evaluated (Tesar 1988).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Continuous infusions have also been used with doses in the range of 0.5 to 2 mg/hour with an optional loading dose of 2.5 mg (Reade 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Nausea and vomiting in advanced or terminal illness (palliative care; off-label use): </b>Oral, SubQ (off-label route): Initial: 1.5 to 3 mg/day; titrate daily based on response and tolerability up to a maximum of 6 mg per 24 hours (Hardy 2010; Mercadante 1995). Additional data may be necessary to further define the role of haloperidol in this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Nausea and vomiting in advanced cancer (Glare 2008):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: 1.5 to 2.5 mg once or twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">SubQ: 1 to 2 mg 2 to 3 times a day <b>or</b> as a continuous subcutaneous infusion at 1 to 5 mg per 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Obsessive-compulsive disorder (off-label use):</b> Oral: Initial: 2 mg/day; adjust dose based on response and tolerability by 2 mg every 3 days up to a maximum dose of 10 mg/day. Average dose in clinical trial was 6 mg/day (McDougle 1994). Additional data may be necessary to further define the role of haloperidol in this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Postoperative nausea and vomiting (PONV), prevention (off-label use):</b> IM, IV (off-label route): 0.5 to 2 mg (Gan 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Rapid tranquilization (agitation/aggression/violent behavior) (off-label use):</b> IM (as lactate): 2.5 to 10 mg (Clinton 1987; MacDonald 2012; Ostinelli 2017; Wilson 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Discontinuation of therapy:</b> The manufacturer and the American Psychiatric Association (APA), Canadian Psychiatric Association (CPA), and World Federation of Societies of Biological Psychiatry (WFSBP) guidelines recommend gradually tapering antipsychotics to avoid withdrawal symptoms and minimize the risk of relapse (APA [Lehman 2004]; Cerovecki 2013; CPA [Addington 2005]; WFSBP [Hasan 2012]); risk for withdrawal symptoms may be highest with highly anti-cholinergic or dopaminergic antipsychotics (Cerovecki 2013). When stopping antipsychotic therapy in patients with schizophrenia, the CPA guidelines recommend a gradual taper over 6 to 24 months, and the APA guidelines recommend reducing the dose by 10% each month (APA [Lehman 2004]; CPA [Addington 2005]). Continuing anti-parkinsonism agents for a brief period after discontinuation may prevent withdrawal symptoms (Cerovecki 2013). When switching antipsychotics, 3 strategies have been suggested: cross-titration (gradually discontinuing the first antipsychotic while gradually increasing the new antipsychotic), overlap and taper (maintaining the dose of the first antipsychotic while gradually increasing the new antipsychotic, then tapering the first antipsychotic), and abrupt change (abruptly discontinuing the first antipsychotic and either increasing the new antipsychotic gradually or starting it at a treatment dose). Evidence supporting ideal switch strategies and taper rates is limited, and results are conflicting (Cerovecki 2013; Remington 2005).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178580\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=haloperidol-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Haloperidol: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Behavior disorders, nonpsychotic:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children 3 to 12 years weighing 15 to 40 kg: Oral: Initial: 0.5 mg/day in 2 to 3 divided doses; may increase by 0.5 mg every 5 to 7 days to usual maintenance range of 0.05 to 0.075 mg/kg/day in 2 to 3 divided doses; maximum dose not established; children with severe, nonpsychotic disturbance may require higher doses; however, no improvement has been shown with doses &gt;6 mg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children &gt;40 kg and Adolescents (off-label dose): Oral: 0.5 to 15 mg/day in 2 to 3 divided doses; begin at lower end of the range and may increase as needed (no more frequently than every 5 to 7 days); maximum daily dose: 15 mg/day. <b>Note:</b> Higher doses may be necessary in severe or refractory cases (Kliegman 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Psychosis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children 3 to 12 years weighing 15 to 40 kg: Oral: Initial: 0.5 mg/day in 2 to 3 divided doses; increase by 0.5 mg every 5 to 7 days to usual maintenance range of 0.05 to 0.15 mg/kg/day in 2 to 3 divided doses; higher doses may be necessary in severe or refractory cases; maximum dose not established; in adolescents, the maximum daily dose is 15 mg/day (Kliegman 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children &gt;40 kg and Adolescents (off-label dose):  Oral: 0.5 to 15 mg/day in 2 to 3 divided doses; begin at lower end of the range and may increase as needed (no more frequently than every 5 to 7 days); maximum daily dose: 15 mg/day (Kliegman 2011; Willner 1969). <b>Note:</b> Higher doses may be necessary in severe or refractory cases (Kliegman 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tourette syndrome: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children 3 to 12 years weighing 15 to 40 kg: Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Manufacturer's labeling: Initial: 0.5 mg/day in 2 to 3 divided doses; increase by 0.5 mg every 5 to 7 days to usual maintenance of 0.05 to 0.075 mg/kg/day in 2 to 3 divided doses; maximum dose not established; however, no improvement has been shown with doses &gt;6 mg/day in patients with nonpsychotic disturbances</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Alternate dosing: Initial: 0.25 to 0.5 mg/day in 2 to 3 divided doses titrated to a usual daily dose range of 1 to 4 mg/day (Roessner 2011; Scahill 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children &gt;40 kg and Adolescents (off-label dose): Oral: 0.25 to 15 mg/day in 2 to 3 divided doses; begin at lower end of the range and may increase as needed (no more frequently than every 5 to 7 days) (Kleigman 2011; Roessner 2011); usual dose range: 1 to 4 mg/day (Roessner 2011; Scahill 2006); maximum dose not established; however, no improvement has been shown with doses &gt;6 mg/day in patients with nonpsychotic disturbances</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178558\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Psychosis:</b> Oral: 0.5 to 2 mg 2 to 3 times daily; adjust dose based on response and tolerability. Maximum dosage per manufacturer&rsquo;s labeling: 100 mg/day. Recommended dose range for schizophrenia: 5 to 20 mg/day (APA [Lehman 2004]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Psychosis/agitation associated with dementia (off-label use):</b> Oral: Initial: 0.25 to 2 mg daily; slowly increase dose based on response and tolerability every 4 to 7 days in increments of 0.25 to 1 mg (De Deyn 1999; Devanand 1998); doses up to 6 mg/day in 1 to 2 divided doses were evaluated in clinical trials (Lonergan 2002). APA guidelines recommend against the first-line use of haloperidol for non-emergent situations (ie, longer-term treatment). If used, in patients without a clinically significant response after 4 weeks, taper and withdraw therapy. In patients with an adequate response, attempt to taper and withdraw therapy within 4 months, unless symptoms recurred with a previous taper attempt. Assess symptoms at least monthly during taper and for at least 4 months after withdrawal of therapy (APA [Reus 2016]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178559\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15897441\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178524\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Concentrate, Oral, as lactate [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2 mg/mL (5 mL, 15 mL, 120 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intramuscular, as decanoate [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Haldol Decanoate: 50 mg/mL (1 mL); 100 mg/mL (1 mL) [contains benzyl alcohol, sesame oil]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg/mL (1 mL, 5 mL); 100 mg/mL (1 mL, 5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as lactate [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Haldol: 5 mg/mL (1 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg/mL (1 mL, 10 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as lactate [strength expressed as base, preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg/mL (1 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.5 mg, 1 mg, 2 mg, 5 mg, 10 mg, 20 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178509\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178529\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection oil (decanoate): The decanoate injectable formulation should be administered IM only, <b>do not administer decanoate IV.</b> A 21-gauge needle is recommended. The maximum volume per injection site should not exceed 3 mL. Z-track injection techniques are recommended to limit leakage after injections (Baweja 2012; Gillespie 2013; McEvoy 2006). Experts recommend administering in the gluteal muscle by deep IM injection, however haloperidol by deltoid injection has been studied with positive results (Baweja 2012; Gillespie 2013; McEvoy 2014; Sassa 2002; Yasuhara 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection solution (lactate): The lactate injectable formulation may be administered IM or IV (off-label route).  Rate of IV administration not well defined; rates of a maximum of 5 mg/minute (Lerner 1979) and 0.125 mg/kg (in 10 mL NS) over 1 to 2 minutes (Magliozzi 1985) have been reported.  <b>Note:</b> IV administration has been associated with QT prolongation and the manufacturer recommends ECG monitoring for QT prolongation and arrhythmias. Consult individual institutional policies and procedures prior to administration. Subcutaneous administration has also been reported (usually in the palliative care setting), either as intermittent administration or as a continuous subcutaneous infusion (Glare 2008, Hardy 2010, Mercadante 1995).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178528\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Behavioral disorders (tablet, concentrate):</b> Treatment of severe behavioral problems in children with combative, explosive hyperexcitability that cannot be accounted for by immediate provocation. Reserve for use in these children only after failure to respond to psychotherapy or medications other than antipsychotics. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hyperactivity (tablet, concentrate):</b> Short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggression, mood lability, or poor frustration tolerance. Reserve for use in these children only after failure to respond to psychotherapy or medications other than antipsychotics. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Psychotic disorders (tablet, concentrate):</b>  Management of manifestations of psychotic disorders. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Schizophrenia: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM, lactate: Treatment of schizophrenia. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM, decanoate: Treatment of patients with schizophrenia who require prolonged parenteral antipsychotic therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Tourette disorder (tablet, concentrate, IM lactate):</b> Control of tics and vocal utterances in Tourette syndrome in adults and children. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25474798\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Chemotherapy-associated nausea and vomiting (breakthrough) (adults); Chorea of Huntington disease; Delirium in the intensive care unit (treatment); Nausea and vomiting in advanced or terminal illness; Obsessive-compulsive disorder; Postoperative nausea and vomiting, prevention; Psychosis/agitation associated with dementia; Rapid tranquilization (agitation/aggression/violent behavior)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178612\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Haldol may be confused with Halcion, Halog, Stadol</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Antipsychotics are identified in the Beers Criteria as potentially inappropriate medications to be avoided in patients 65 years and older with dementia due to an increased risk of mortality, cerebrovascular accidents (stroke), and a greater rate of cognitive decline with use; avoid antipsychotics for behavioral problems associated with dementia or delirium unless alternative nonpharmacologic therapies have failed and patient may harm self or others. Use <i>may be appropriate</i> in geriatric patients with schizophrenia, bipolar disorder, or for short-term use as an antiemetic during chemotherapy. In addition, antipsychotics should be used with caution in older adults due to their potential to cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatremia; monitor sodium closely with initiation or dosage adjustments in older adults (Beers Criteria [AGS 2015]).</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Haldol [U.S. and multiple international markets] may be confused with Halotestin brand name for fluoxymesterone [Great Britain]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178516\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%: Central nervous system: Extrapyramidal reaction (lactate: 51%; oral: &lt;1%), parkinsonian-like syndrome (decanoate: 31%; lactate and oral: &lt;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dystonia (lactate: 7%; decanoate and oral: &lt;1%), hypertonia (lactate: 7%; decanoate and oral: &lt;1%), drowsiness (lactate: 5%; decanoate and oral: &lt;1%), akathisia (decanoate: 3%; lactate and oral: &lt;1%), headache (decanoate: 3%; lactate and oral: &lt;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Constipation (lactate: 4%; decanoate and oral: &lt;1%), abdominal pain (decanoate: 3%), xerostomia (&le;2%), sialorrhea (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Hyperkinesia (lactate: 10%), tremor (3% to 8%), bradykinesia (lactate: 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Oculogyric crisis (decanoate: 6%; lactate: &lt;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Anxiety, euphoria, lethargy, psychotic symptoms (exacerbation), vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Diaphoresis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hyperglycemia, hyponatremia, increased libido, menstrual disease</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Anorexia, diarrhea, dyspepsia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Breast engorgement, impotence, lactation</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Cataract, retinopathy, visual disturbance</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Increased depth of respiration</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abnormal hepatic function tests, acneiform eruption, acute hepatic failure, agitation, agranulocytosis, akathisia, alopecia, amenorrhea, anaphylaxis, anemia, blurred vision, bronchopneumonia, bronchospasm, cardiac arrhythmia, cholestasis, cogwheel rigidity, confusion, decreased libido, depression, dizziness, dyskinesia, dysmenorrhea, dyspnea, edema, erectile dysfunction, exfoliative dermatitis, extrasystoles, facial edema, galactorrhea, gynecomastia, heatstroke, hepatic insufficiency, hepatitis, hyperammonemia, hyperhidrosis, hyperprolactinemia, hyperpyrexia, hypersensitivity angiitis, hypersensitivity reaction, hypertension, hyperthermia, hypoglycemia, hypokinesia, hypotension, hypothermia, injection site reaction, insomnia, jaundice, laryngeal edema, laryngospasm, leukocytosis, leukopenia, lymphocytosis with monocytosis, maculopapular rash, mask-like face, mastalgia, menorrhagia, motor dysfunction, muscle rigidity, muscle twitching, nausea, neonatal withdrawal, neuroleptic malignant syndrome, neutropenia, nystagmus, opisthotonus, orthostatic hypotension, pancytopenia, priapism, prolonged Q-T interval on ECG, pruritus, restlessness, rhabdomyolysis, sedation, seizure, SIADH, skin photosensitivity, skin rash, tachycardia, tardive dyskinesia, tardive dystonia, thrombocytopenia, torsades de pointes, torticollis, trismus, urinary retention, urticaria, ventricular arrhythmia, ventricular fibrillation, ventricular tachycardia, vomiting, weight gain, weight loss</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178532\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to haloperidol or any component of the formulation; Parkinson disease; severe CNS depression; coma</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling</i>: Additional contraindications (not in US labeling): Significant depressive states; previous spastic diseases; young children</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178513\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Altered cardiac conduction: Cases of sudden death, QT prolongation, and torsades de pointes have been reported with haloperidol use; risk may be increased with doses exceeding recommendations and/or intravenous administration (off-label route) of intramuscular lactate injection. Use with caution or avoid use in patients with electrolyte abnormalities (eg, hypokalemia, hypomagnesemia), hypothyroidism, familial long QT syndrome, concomitant medications which may augment QT prolongation, or any underlying cardiac abnormality which may also potentiate risk. Prior to initiation of intravenous therapy, obtain a baseline ECG. Consider continuous ECG monitoring, especially if the patient has risk factors for QTc prolongation, the baseline ECG reveals a prolonged QTc, or cumulative doses of &ge;2 mg are needed. Monitor electrolyte concentrations throughout therapy. If the baseline QTc interval increases by 20% to 25%, increases &gt;500 msec, or if T-waves flatten or U-waves develop on the ECG, reduce the dosage or consider alternative therapy (Hassballa 2003; Meyer-Massetti 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anticholinergic effects: May cause anticholinergic effects (constipation, xerostomia, blurred vision, urinary retention); use with caution in patients with decreased gastrointestinal motility, paralytic ileus, urinary retention, BPH, xerostomia, or visual problems. Relative to other neuroleptics, haloperidol has a low potency of cholinergic blockade (Richelson 1999).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Blood dyscrasias: Leukopenia, neutropenia, and agranulocytosis (sometimes fatal) have been reported in clinical trials and postmarketing reports with antipsychotic use; presence of risk factors (eg, preexisting low WBC or history of drug-induced leuko-/neutropenia) should prompt periodic blood count assessment. Discontinue therapy at first signs of blood dyscrasias or if absolute neutrophil count &lt;1,000/mm<sup>3</sup>.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery, driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Esophageal dysmotility/aspiration: Antipsychotic use has been associated with esophageal dysmotility and aspiration; use with caution in patients at risk of pneumonia (ie, Alzheimer disease) (Maddalena 2004).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extrapyramidal symptoms: May cause extrapyramidal symptoms (EPS), including pseudoparkinsonism, acute dystonic reactions, akathisia, and tardive dyskinesia. Risk of dystonia (and possibly other EPS) may be greater with increased doses, use of conventional antipsychotics, males, and younger patients. Factors associated with greater vulnerability to tardive dyskinesia include older in age, female gender combined with postmenopausal status, Parkinson disease, pseudoparkinsonism symptoms, affective disorders (particularly major depressive disorder), concurrent medical diseases such as diabetes, previous brain damage, alcoholism, poor treatment response, and use of high doses of antipsychotics (APA [Lehman 2004]; Soares-Weiser 2007). Consider therapy discontinuation with signs/symptoms of tardive dyskinesia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Falls: May increase the risk for falls due to somnolence, orthostatic hypotension, and motor or sensory instability. Complete fall risk assessments at baseline and periodically during treatment in patients with diseases or on medications that may also increase fall risk.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperprolactinemia: May increase prolactin levels; clinical significance of hyperprolactinemia in patients with breast cancer or other prolactin-dependent tumors is unknown.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neuroleptic malignant syndrome (NMS): Use may be associated with NMS; monitor for mental status changes, fever, muscle rigidity, and/or autonomic instability. Following recovery from NMS, reintroduction of drug therapy should be carefully considered; if an antipsychotic agent is resumed, allow at least 2 weeks to elapse after recovery before rechallenge, consider a lower potency antipsychotic and monitor closely for the reemergence of NMS (Strawn 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Orthostatic hypotension: May cause orthostatic hypotension; use with caution in patients at risk of this effect or in those who would not tolerate transient hypotensive episodes (cerebrovascular disease, cardiovascular disease, hypovolemia, or concurrent medication use that may predispose to hypotension/bradycardia). Relative to other neuroleptics, the risk of orthostatic hypotension is low (APA [Lehman 2004]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Temperature regulation: Impaired core body temperature regulation may occur; caution with strenuous exercise, heat exposure, dehydration, and concomitant medication possessing anticholinergic effects (Kwok 2005; Martinez 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with severe cardiovascular disease because of the possibility of transient hypotension and/or precipitation of angina pain.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bipolar disorder: Use with caution in patients with bipolar disorder; when used to control mania, there may be a rapid mood swing to depression. Haloperidol does not possess antidepressant effects (Cipriani 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dementia: <b>[US Boxed Warning]: Elderly patients with dementia-related psychosis treated with antipsychotics are at an increased risk of death compared to placebo.</b> Most deaths appeared to be either cardiovascular (eg, heart failure, sudden death) or infectious (eg, pneumonia) in nature. Avoid the first-line use of oral haloperidol in elderly patients with dementia-related psychosis due to a greater risk of harm relative to other antipsychotics (APA [Reus 2016]). Haloperidol is not approved for the treatment of dementia-related psychosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Glaucoma: Use with caution in patients with narrow-angle glaucoma; condition may be exacerbated by cholinergic blockade (APA [Lehman 2004]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Parkinson disease: Use is contraindicated in patients with Parkinson disease; these patients may be more sensitive to adverse effects (APA [Lehman 2004]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure disorder: Use with caution in patients at risk of seizures, including those with a history of seizures, EEG abnormalities, or concurrent anticonvulsant therapy; haloperidol may lower the seizure threshold.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thyroid dysfunction: Avoid in thyrotoxicosis; severe neurotoxicity (rigidity, inability to walk or talk) may occur with use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Increased risk for developing tardive dyskinesia, particularly elderly women.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Discontinuation of therapy: When discontinuing antipsychotic therapy, the manufacturer and the American Psychiatric Association (APA), Canadian Psychiatric Association (CPA), and World Federation of Societies of Biological Psychiatry (WFSBP) guidelines recommend gradually tapering antipsychotics to avoid physical withdrawal symptoms, including anorexia, anxiety, diaphoresis, diarrhea, dizziness, dyskinesia, headache, myalgia, nausea, paresthesia, restlessness, tremulousness, and vomiting (APA [Lehman 2004]; CPA [Addington 2005]; Lambert 2007; WFSBP [Hasan 2012]). The risk of withdrawal symptoms is highest following abrupt discontinuation of highly anti-cholinergic or dopaminergic antipsychotics (Cerovecki 2013). Additional factors such as duration of antipsychotic exposure, the indication for use, medication half-life, and risk for relapse should be considered. In schizophrenia, there is no reliable indicator to differentiate the minority who will not from the majority who will relapse with drug discontinuation. However, studies in which the medication of well-stabilized patients were discontinued indicate that 75% of patients relapse within 6 to 24 months. Indefinite maintenance antipsychotic medication is generally recommended, and especially for patients who have had multiple prior episodes or 2 episodes within 5 years (APA [Lehman 2004]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Parenteral administration: Hypotension may occur, particularly with parenteral administration. Risk of QT prolongation, torsade de pointes, and sudden death appear to be increased with intravenous administration, particularly at higher doses. Although the short-acting form (lactate) is used clinically intravenously, the IV use of the injection is not an FDA-approved route of administration; the decanoate form should never be administered intravenously.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178598\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP1A2 (minor), CYP2D6 (major), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178518\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8516&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AbobotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acetylcholinesterase Inhibitors: May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acetylcholinesterase Inhibitors (Central): May enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifampridine: May diminish the anticholinergic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Amifampridine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amisulpride: Antipsychotic Agents may enhance the adverse/toxic effect of Amisulpride. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: Antipsychotic Agents may diminish the stimulatory effect of Amphetamines. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticholinergic Agents: May enhance the adverse/toxic effect of other Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anti-Parkinson Agents (Dopamine Agonist): Antipsychotic Agents (First Generation [Typical]) may diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist). Anti-Parkinson Agents (Dopamine Agonist) may diminish the therapeutic effect of Antipsychotic Agents (First Generation [Typical]).  Management: Avoid concomitant therapy if possible and monitor for decreased effects of both agents when these combinations cannot be avoided. Atypical antipsychotics such as clozapine and quetiapine may be less likely to reduce the effects of anti-Parkinson agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ARIPiprazole: May enhance the QTc-prolonging effect of Haloperidol. ARIPiprazole may diminish the therapeutic effect of Haloperidol. Haloperidol may increase the serum concentration of ARIPiprazole. Management: See full interaction monograph.  Aripiprazole dose adjustment may not be required when used as adjunctive therapy for major depressive disorder.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Asunaprevir: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May enhance the adverse/toxic effect of Antipsychotic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine patches (Butrans brand) at 5 mcg/hr in adults when used with other CNS depressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BuPROPion: May enhance the neuroexcitatory and/or seizure-potentiating effect of Agents With Seizure Threshold Lowering Potential.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: May decrease the serum concentration of Haloperidol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloral Betaine: May enhance the adverse/toxic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ChlorproMAZINE: May enhance the QTc-prolonging effect of Haloperidol. Haloperidol may increase the serum concentration of ChlorproMAZINE. ChlorproMAZINE may increase the serum concentration of Haloperidol. Management: Consider alternatives to combined treatment with these agents. If combined treatment cannot be avoided, monitor for signs and symptoms of prolonged QTc interval (e.g. arrhythmias).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxylamine: May enhance the CNS depressant effect of CNS Depressants. Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is  not recommended.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eluxadoline: Anticholinergic Agents may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">FLUoxetine: May enhance the QTc-prolonging effect of Haloperidol. FLUoxetine may increase the serum concentration of Haloperidol.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">FluvoxaMINE: May increase the serum concentration of Haloperidol. Management: Monitor for increased haloperidol concentrations/effects when patients are receiving fluvoxamine, particularly when fluvoxamine dose is 150 mg/day or greater.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal Agents (Prokinetic): Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glucagon: Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glycopyrrolate (Oral Inhalation): Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glycopyrrolate (Systemic): May decrease the serum concentration of Haloperidol. Management: Monitor patients closely for signs/symptoms of reduced clinical response to haloperidol if concurrent use with glycopyrrolate is required.  When possible, consider avoiding concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Guanethidine: Antipsychotic Agents may diminish the therapeutic effect of Guanethidine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CNS Depressants may enhance the CNS depressant effect of HYDROcodone.  Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hydroxychloroquine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Imatinib: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iohexol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iohexol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iomeprol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iopamidol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kava Kava: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levosulpiride: Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lithium: May enhance the neurotoxic effect of Antipsychotic Agents. Lithium may decrease the serum concentration of Antipsychotic Agents. Specifically noted with chlorpromazine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mequitazine: Antipsychotic Agents may enhance the arrhythmogenic effect of Mequitazine.  Management: Consider alternatives to one of these agents when possible.  While this combination is not specifically contraindicated, mequitazine labeling describes this combination as discouraged.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: Antipsychotic Agents may enhance the adverse/toxic effect of Methylphenidate. Methylphenidate may enhance the adverse/toxic effect of Antipsychotic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metoclopramide: May enhance the adverse/toxic effect of Antipsychotic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: May enhance the adverse/toxic effect of Antipsychotic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mianserin: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocycline: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Netupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroglycerin: Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OnabotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: CNS Depressants may enhance the CNS depressant effect of Opioid Analgesics.  Management: Avoid concomitant use of opioid analgesics and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxatomide: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Panobinostat: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Management: Avoid concurrent use of sensitive CYP2D6 substrates when possible, particularly those substrates with a narrow therapeutic index.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perhexiline: CYP2D6 Substrates (High risk with Inhibitors) may increase the serum concentration of Perhexiline. Perhexiline may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piribedil: Antipsychotic Agents may diminish the therapeutic effect of Piribedil. Piribedil may diminish the therapeutic effect of Antipsychotic Agents.  Management: Use of piribedil with antiemetic neuroleptics is contraindicated, and use with antipsychotic neuroleptics, except for clozapine, is not recommended.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium Citrate: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramlintide: May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probucol: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): May enhance the QTc-prolonging effect of other QTc-Prolonging Agents (Moderate Risk). Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: Antipsychotic Agents may diminish the therapeutic effect of Quinagolide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNIDine: Haloperidol may enhance the QTc-prolonging effect of QuiNIDine. QuiNIDine may increase the serum concentration of Haloperidol. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ramosetron: Anticholinergic Agents may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RimabotulinumtoxinB: Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Saquinavir: Haloperidol may enhance the arrhythmogenic effect of Saquinavir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.  Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin Modulators: May enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<b> Exceptions: </b>Nicergoline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulpiride: Antipsychotic Agents may enhance the adverse/toxic effect of Sulpiride. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tapentadol: May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tiotropium: Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Umeclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Urea Cycle Disorder Agents: Haloperidol may diminish the therapeutic effect of Urea Cycle Disorder Agents. More specifically, Haloperidol may increase plasma ammonia concentrations and thereby increase the doses of Urea Cycle Disorder Agents needed to maintain concentrations in the target range. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vinflunine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Xipamide: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178520\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10869024\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies. Haloperidol crosses the placenta in humans (Newport 2007). Although haloperidol has not been found to be a major human teratogen, an association with limb malformations following first trimester exposure in humans cannot be ruled out (ACOG 2008; Diav-Citrin 2005). Antipsychotic use during the third trimester of pregnancy has a risk for abnormal muscle movements (extrapyramidal symptoms [EPS]) and withdrawal symptoms in newborns following delivery. Symptoms in the newborn may include agitation, feeding disorder, hypertonia, hypotonia, respiratory distress, somnolence, and tremor; these effects may be self-limiting or require hospitalization. If needed, the minimum effective maternal dose should be used in order to decrease the risk of EPS (ACOG 2008). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178535\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Haloperidol is found in breast milk and has been detected in the plasma and urine of breastfeeding infants (Whalley 1981; Yoshida 1999). Breast engorgement, gynecomastia, and lactation are known side effects with the use of haloperidol. Breastfeeding is not recommended by the manufacturer.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178522\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Mental status; vital signs (as clinically indicated); ECG (as clinically indicated and with off-label intravenous administration); weight, height, BMI, waist circumference (baseline; at every visit for the first 6 months; quarterly with stable antipsychotic dose); CBC (as clinically indicated; monitor frequently during the first few months of therapy in patients with preexisting low WBC or history of drug-induced leukopenia/neutropenia); electrolytes and liver function (annually and as clinically indicated); fasting plasma glucose level/ HbA<sub>1c</sub> (baseline, then yearly; in patients with diabetes risk factors or if gaining weight repeat 4 months after starting antipsychotic, then yearly); lipid panel (baseline; repeat every 2 years if LDL level is normal; repeat every 6 months if LDL level is &gt;130 mg/dL); changes in menstruation, libido, development of galactorrhea, erectile and ejaculatory function (at each visit for the first 12 weeks after the antipsychotic is initiated or until the dose is stable, then yearly); abnormal involuntary movements or parkinsonian signs (baseline; repeat weekly until dose stabilized for at least 2 weeks after introduction and for 2 weeks after any significant dose increase); tardive dyskinesia (every 6 months; high-risk patients every 3 months); visual changes (inquire yearly); ocular examination (yearly in patients &gt;40 years; every 2 years in younger patients) (ADA 2004; Lehman 2004; Marder 2004).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <i>ICU delirium:</i> Monitor either the Confusion Assessment Method for the ICU (CAM-ICU) or the Intensive Care Delirium Screening Checklist (ICDSC)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178525\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Schizophrenia: Therapeutic drug monitoring is not routinely warranted; a clear correlation between plasma concentrations and therapeutic response has not been demonstrated. Clinical studies suggest a therapeutic window may range from 5 to 18 ng/mL (SI: 10 to 48 nmol/L) (Boyer 1984; Mitchell 2001) with concerns for toxicity at levels &gt;50 ng/mL (SI: &gt;133 nmol/L) (Darby 1995)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178512\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Haloperidol is a butyrophenone antipsychotic that nonselectively blocks postsynaptic dopaminergic D<sub>2</sub> receptors in the brain (Richelson 1999; Risch 1996).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178531\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IV: V<sub>z</sub>: 9.5 to 21.7 L/kg (Kudo 1999) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oral: V<sub>z</sub>/F: 52.6 &plusmn; 14.5 L/kg (Kudo 1999)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 88.4% to 92.5% (Kudo 1999) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic: 50% to 60% glucuronidation (inactive); 23% CYP3A4-mediated reduction to inactive metabolites (some back-oxidation to haloperidol); and 20% to 30% CYP3A4-mediated N-dealkylation, including minor oxidation pathway to toxic pyridinium derivative (Kudo 1999)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Oral: 60% to 70% (Kudo 1999)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Decanoate: 21 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lactate:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">IM: 20 hours (Kudo 1999)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">IV: 14 to 26 hours (Kudo 1999) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Oral: 14 to 37 hours (Kudo 1999)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Decanoate: 6 days </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lactate:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">IM: 20 minutes (Kudo 1999)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Oral: 2 to 6 hours (Kudo 1999)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (30%, 1% as unchanged drug) (Kudo 1999)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178534\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Concentrate</b> (Haloperidol Lactate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg/mL (120 mL): $54.32</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Haldol Decanoate Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/mL (1 mL): $104.49</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/mL (1 mL): $199.19</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Haldol Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/mL (1 mL): $24.76</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Haloperidol Decanoate Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/mL (1 mL): $33.70</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/mL (1 mL): $61.78</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Haloperidol Lactate Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/mL (1 mL): $1.92</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Haloperidol Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mg (100): $32.55</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (100): $46.14</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (100): $63.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (100): $102.38</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $179.31</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (100): $275.70</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178536\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aloperidin (GR);</li>\n      <li>Avant (MT);</li>\n      <li>Decadol (PL);</li>\n      <li>Haldol (AT, BB, BE, BH, BZ, CL, CY, DE, EG, GB, HR, IE, IS, JO, KW, LB, LU, MT, MX, NI, NO, NZ, PA, PE, PH, PK, PT, QA, RO, SA, SE, SI, TR, VE);</li>\n      <li>Haldol Decanoas (AE, BF, BG, BH, BJ, BM, BS, CH, CI, CR, CY, CZ, DO, EC, EG, ET, FR, GH, GM, GN, GT, GY, HK, HN, ID, IL, IQ, IR, IT, JM, JO, KE, KR, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, NL, OM, PR, PY, QA, SA, SC, SD, SL, SN, SR, SV, SY, TN, TT, TW, TZ, UG, UY, YE, ZM, ZW);</li>\n      <li>Haldol decanoas (LU);</li>\n      <li>Haldol Decanoate (AU, BB);</li>\n      <li>Haldol Decanoato (BR, CL);</li>\n      <li>Haldol depo (HR);</li>\n      <li>Haldol Depot (NO);</li>\n      <li>Halop (BD);</li>\n      <li>Haloper (DE, HK, RU);</li>\n      <li>Haloperidol Decanoat (HU);</li>\n      <li>Haloperidol Esteve (ES);</li>\n      <li>Haloperidol Prodes (ES);</li>\n      <li>Haloperidol-ratiopharm (LU);</li>\n      <li>Haloperil (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Halopidol decanoato (AR, CO);</li>\n      <li>Halopryl (UA);</li>\n      <li>Haloslip (LK);</li>\n      <li>Haloxen (SG);</li>\n      <li>Haridol Decanoate (TH);</li>\n      <li>Haridol-D (CN);</li>\n      <li>Hazidol (VN);</li>\n      <li>Holt (BD);</li>\n      <li>Manace (MY);</li>\n      <li>Mapress (MY);</li>\n      <li>Motivan (SG);</li>\n      <li>Norodol (TR);</li>\n      <li>Peldol (BD);</li>\n      <li>Pericate (IL);</li>\n      <li>Peridol (BD);</li>\n      <li>Perol (BD);</li>\n      <li>Senorm (UA);</li>\n      <li>Senorm L.A. (IN);</li>\n      <li>Seranace (GB, IE, ZA);</li>\n      <li>Seredol Deca (PH);</li>\n      <li>Serenace (AE, BH, CY, GB, JP, LK, MT, PH, QA, SA, SG, TR);</li>\n      <li>Serenase (FI);</li>\n      <li>Serenase Dekanoat (DK);</li>\n      <li>Starhal (VN);</li>\n      <li>Sutran X (PY);</li>\n      <li>Sylador (QA);</li>\n      <li>Zocalm-5 (LK);</li>\n      <li>Zuredel (PH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    ACOG Committee on Practice Bulletins-Obstetrics, &quot;ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists Number 92, April 2008 (Replaces Practice Bulletin Number 87, November 2007). Use of Psychiatric Medications During Pregnancy and Lactation,&quot; <i>Obstet Gynecol</i>, 2008, 111(4):1001-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/18378767/pubmed\" target=\"_blank\" id=\"18378767\">18378767</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. <i>J Clin Psychiatry</i>. 2004;65(2):267-272.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/15003083/pubmed\" target=\"_blank\" id=\"15003083\">15003083</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2015;63(11):2227-2246. doi:10.1111/jgs.13702.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/26446832/pubmed\" target=\"_blank\" id=\"26446832\">26446832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Armstrong MJ, Miyasaki JM; American Academy of Neurology. Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology. <i>Neurology</i>. 2012;79(6):597-603.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/22815556/pubmed\" target=\"_blank\" id=\"22815556\">22815556</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bandelow B, Zohar J, Hollander E, et al; ; WFSBP Task Force on Treatment Guidelines for Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. <i>World J Biol Psychiatry</i>. 2008;9(4):248-312.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/18949648/pubmed\" target=\"_blank\" id=\"18949648\">18949648</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"2962009\"></a>Barr AN, Fischer JH, Koller WC, Spunt AL, Singhal A. Serum haloperidol concentration and choreiform movements in Huntington's disease. <i>Neurology</i>. 1988;38(1): 84-88.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/2962009/pubmed\" target=\"_blank\" id=\"2962009\">2962009</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Barr J, Fraser GL, Puntillo K, et al, &ldquo;Clinical Practice Guidelines for the Management of Pain, Agitation, and Delirium in Adult Patients in the Intensive Care Unit,&rdquo; <i>Crit Care Med</i>, 2013, 41(1):263-306.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/23269131/pubmed\" target=\"_blank\" id=\"23269131\">23269131</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21947834\"></a>Basch E, Prestrud AA, Hesketh PJ, et al; American Society of Clinical Oncology. Antiemetics: American Society of Clinical Oncology clinical practice guideline update [published correction appears in <i>J Clin Oncol</i>. 2014;32(19):2117]. <i>J Clin Oncol</i>. 2011;29(31):4189-4198.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/21947834/pubmed\" target=\"_blank\" id=\"21947834\">21947834</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baweja R, Sedky K, Lippmann S. Long-acting antipsychotic medications. <i>Curr Drug Targets</i>. 2012;13(4):555-560.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/22250654/pubmed\" target=\"_blank\" id=\"22250654\">22250654</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16842168\"></a>Bonelli RM, Wenning GK. Pharmacological management of Huntington's disease: an evidence-based review. <i>Curr Pharm Des</i>. 2006;12(21):2701.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/16842168/pubmed\" target=\"_blank\" id=\"16842168\">16842168</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Boyer WF, Friedel RO. Antidepressant and antipsychotic plasma levels. <i>Psychiatr Clin North Am</i>. 1984;7(3):601-610.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/6148744/pubmed\" target=\"_blank\" id=\"6148744\">6148744</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Buchanan RW, Kreyenbuhl J, Kelly DL, et al; Schizophrenia Patient Outcomes Research Team (PORT). The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. <i>Schizophr Bull</i>. 2010;36(1):71-93. doi: 10.1093/schbul/sbp116.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/19955390/pubmed\" target=\"_blank\" id=\"19955390\">19955390</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15564955\"></a>B&uuml;ttner M, Walder B, von Elm E, Tram&egrave;r MR. Is low-dose haloperidol a useful antiemetic?: A meta-analysis of published and unpublished randomized trials. Anesthesiology. 2004;101(6):1454-1463.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/15564955/pubmed\" target=\"_blank\" id=\"15564955\">15564955</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Canadian Psychiatric Association. Clinical practice guidelines. Treatment of schizophrenia. <i>Can J Psychiatry</i>. 2005;50(13)(suppl 1):7S-57S.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/16529334/pubmed\" target=\"_blank\" id=\"16529334\">16529334</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol&mdash;United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cerovecki A, Musil R, Klimke A, et al. Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations. <i>CNS Drugs</i>. 2013;27(7):545-572. doi: 10.1007/s40263-013-0079-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/23821039/pubmed\" target=\"_blank\" id=\"23821039\">23821039</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cipriani A, Rendell JM, Geddes JR. Haloperidol alone or in combination for acute mania. <i>Cochrane Database Syst Rev</i>. 2006;(3)CD004362.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/16856043/pubmed\" target=\"_blank\" id=\"16856043\">16856043</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"3813167\"></a>Clinton JE, Sterner S, Stelmachers Z, Ruiz E. Haloperidol for sedation of disruptive emergency patients. <i>Ann Emerg Med</i>. 1987;16(3):319-322.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/3813167/pubmed\" target=\"_blank\" id=\"3813167\">3813167</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Darby JK, Pasta DJ, Dabiri L, Clark L, Mosbacher D. Haloperidol dose and blood level variability: toxicity and interindividual and intraindividual variability in the nonresponder patient in the clinical practice setting. <i>J Clin Psychopharmacol</i>. 1995;15(5):334-340.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/8830064/pubmed\" target=\"_blank\" id=\"8830064\">8830064</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    De Deyn PP, Rabheru K, Rasmussen A, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. <i>Neurology</i>. 1999;53(5):946-955.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/10496251/pubmed\" target=\"_blank\" id=\"10496251\">10496251</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Devanand DP, Marder K, Michaels KS, et al. A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease. <i>Am J Psychiatry</i>. 1998;155(11):1512-1520.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/9812111/pubmed\" target=\"_blank\" id=\"9812111\">9812111</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Diav-Citrin O, Shechtman S, Ornoy S, et al, &quot;Safety of Haloperidol and Penfluridol in Pregnancy: A Multicenter, Prospective, Controlled Study,&quot; <i>J Clin Psychiatry</i>, 2005, 66(3):317-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/15766297/pubmed\" target=\"_blank\" id=\"15766297\">15766297</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ereshefsky L, Toney G, Saklad SR, Anderson C, Seidel D. A loading-dose strategy for converting from oral to depot haloperidol. <i>Hosp Communitry Psychiatry</i>. 1993;44(12):1155-1161.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/7907570/pubmed\" target=\"_blank\" id=\"7907570\">7907570</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gan TJ, Diemunsch P, Habib AS, et al; Society for Ambulatory Anesthesia. Consensus guidelines for the management of postoperative nausea and vomiting [published correction appears in <i>Anesth Analg</i>. 2014;118(3):689 and <i>Anesth Analg</i>. 2015;120(2):494]. <i>Anesth Analg</i>. 2014;118(1):85-113.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/24356162/pubmed\" target=\"_blank\" id=\"24356162\">24356162</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gillespie M, Toner A. The safe administration of long-acting depot antipsychotics. <i>Br J Nurs</i>. 2013;22(8):464, 466-469.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/23905227/pubmed\" target=\"_blank\" id=\"23905227\">23905227</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"6147393\"></a>Girotti F, Carella F, Scigliano G, et al. Effect of neuroleptic treatment on involuntary movements and motor performances in Huntington's disease. <i>J Neurol Neurosurg Psychiatry</i>. 1984;47(8):848-852.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/6147393/pubmed\" target=\"_blank\" id=\"6147393\">6147393</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Glare PA, Dunwoodie D, Clark K, et al. Treatment of nausea and vomiting in terminally ill cancer patients. <i>Drugs.</i> 2008;68(18):2575-2590.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/19093700/pubmed\" target=\"_blank\" id=\"19093700\">19093700</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Haldol decanoate injection (haloperidol) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals; December 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Haldol lactate injection (haloperidol) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals; December 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Haloperidol tablets [prescribing information]. Princeton, NJ: Sandoz Inc; July 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Haloperidol lactate oral solution [prescribing information]. Sellersville, PA: Teva Pharmaceuticals; December 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Haloperidol lactate injection [prescribing information]. Schaumburg, IL: Sagent Pharmaceuticals; August 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20619214\"></a>Hardy JR, O&rsquo;Shea A, White C, Gilshenan K, Welch L, Douglas C. The efficacy of haloperidol in the management of nausea and vomiting in patients with cancer. <i>J Pain Symptom Manage</i>. 2010;40(1):111-116.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/20619214/pubmed\" target=\"_blank\" id=\"20619214\">20619214</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hasan A, Falkai P, Wobrock T, et al; WFSBP Task force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. <i>World J Biol Psychiatry</i>. 2013;14(1):2-44. doi: 10.3109/15622975.2012.739708.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/23216388/pubmed\" target=\"_blank\" id=\"23216388\">23216388</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hasan A, Falkai P, Wobrock T, et al; World Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. <i>World J Biol Psychiatry</i>. 2012;13(5):318-378. doi: 10.3109/15622975.2012.696143.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/22834451/pubmed\" target=\"_blank\" id=\"22834451\">22834451</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hassaballa HA, Balk RA. Torsade de pointes associated with the administration of intravenous haloperidol: a review of the literature and practical guidelines for use. <i>Expert Opin Drug Saf</i>. 2003;2(6):543-547.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/14585064/pubmed\" target=\"_blank\" id=\"14585064\">14585064</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Stanton BF, St. Geme Ill JW, Schor NF, Behrman RE, eds. <i>Nelson Textbook of Pediatrics</i>. 19th ed. Philadelphia, PA: Elsevier Saunders; 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"3162109\"></a>Koller WC, Trimble J. The gait abnormality of Huntington's disease. <i>Neurology</i>. 1985;35(10):1450-1454.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/3162109/pubmed\" target=\"_blank\" id=\"3162109\">3162109</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Koran LM, Hanna GL, Hollander E, Gerald N, Simpson HB; American Psychiatric Association. Practice guideline for the treatment of patients with obsessive-compulsive disorder. <i>Am J Psychiatry</i>. 2007;164(7)(suppl):5-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/17849776/pubmed\" target=\"_blank\" id=\"17849776\">17849776</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kudo S and Ishizaki T, &quot;Pharmacokinetics of Haloperidol: An Update,&quot; <i>Clin Pharmacokinet</i>, 1999, 73(6):435-56.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kwok JS, Chan TY. Recurrent heat-related illnesses during antipsychotic treatment. <i>Ann Pharmacother</i>. 2005;39(11):1940-1942.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/16174785/pubmed\" target=\"_blank\" id=\"16174785\">16174785</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lambert TJ. Switching antipsychotic therapy: what to expect and clinical strategies for improving therapeutic outcomes. <i>J Clin Psychiatry</i>. 2007;68(suppl 6):10-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/17650054/pubmed\" target=\"_blank\" id=\"17650054\">17650054</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"9818639\"></a>Lanct&ocirc;t KL, Best TS, Mittmann N, et al. Efficacy and safety of neuroleptics in behavioral disorders associated with dementia. <i>J Clin Psychiatry</i>. 1998;59(10):550-561; quiz 562-563.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/9818639/pubmed\" target=\"_blank\" id=\"9818639\">9818639</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lehman AF, Lieberman JA, Dixon LB, et al; American Psychiatric Association; Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition. <i>Am J Psychiatry</i>. 2004;161(2)(suppl):1-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/15000267/pubmed\" target=\"_blank\" id=\"15000267\">15000267</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lerner Y, Lwow E, Levitin A, Belmaker RH. Acute high-dose parenteral haloperidol treatment of psychosis. <i>Am J Psychiatry</i>. 1979;136(8):1061-1064.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/380367/pubmed\" target=\"_blank\" id=\"380367\">380367</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15960567\"></a>Li X, May RS, Tolbert LC, Jackson WT, Flournoy JM, Baxter LR. Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive compulsive disorder: a crossover study. <i>J Clin Psychiatry</i>. 2005;66:736&ndash;743.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/15960567/pubmed\" target=\"_blank\" id=\"15960567\">15960567</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18391612\"></a>Lohr L. Chemotherapy-induced nausea and vomiting. <i>Cancer J</i>. 2008;14(2):85-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/18391612/pubmed\" target=\"_blank\" id=\"18391612\">18391612</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12076456\"></a>Lonergan E, Luxenberg J, Colford J. Haloperidol for agitation in dementia. <i>Cochrane Database Syst Rev</i>. 2002;(2):CD002852.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/12076456/pubmed\" target=\"_blank\" id=\"12076456\">12076456</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22544013\"></a>MacDonald K, Wilson M, Minassian A, et al. A naturalistic study of intramuscular haloperidol versus intramuscular olanzapine for the management of acute agitation. <i>J Clin Psychopharmacol</i>. 2012;32(3):317-322.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/22544013/pubmed\" target=\"_blank\" id=\"22544013\">22544013</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Maddalena AS, Fox M, Hofmann M, Hock C. Esophageal dysfunction on psychotropic medication. A case report and literature review. <i>Pharmacopsychiatry</i>. 2004;37(3):134-138.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/15138897/pubmed\" target=\"_blank\" id=\"15138897\">15138897</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Magliozzi JR, Gillespie H, Lombrozo L, Hollister LE. Mood alteration following oral and intravenous haloperidol and relationship to drug concentration in normal subjects. <i>J Clin Pharmacology</i>. 1985;25(4):285-290.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/4008674/pubmed\" target=\"_blank\" id=\"4008674\">4008674</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. <i>Am J Psychiatry</i>. 2004;161(8):1334-1349.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/15285957/pubmed\" target=\"_blank\" id=\"15285957\">15285957</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Martinez M, Devenport L, Saussy J, Martinez J. Drug-associated heat stroke. <i>South Med J</i>. 2002;95(8):799-802.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/12190212/pubmed\" target=\"_blank\" id=\"12190212\">12190212</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"8161290\"></a>McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. <i>Arch Gen Psychiatry</i>. 1994;51(4):302.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/8161290/pubmed\" target=\"_blank\" id=\"8161290\">8161290</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McEvoy JP, Byerly M, Hamer RM, et al. Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial. <i>JAMA</i>. 2014;311(19):1978-1987.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/24846035/pubmed\" target=\"_blank\" id=\"24846035\">24846035</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McEvoy JP. Risks versus benefits of different types of long-acting injectable antipsychotics. <i>J Clin Psychiatry</i>. 2006;67(suppl 5):15-18.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/16822092/pubmed\" target=\"_blank\" id=\"16822092\">16822092</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"7544674\"></a>Mercadante S. Bowel obstruction in home-care cancer patients: 4 years experience. <i>Support Care Cancer</i>. 1995;3(3):190-193.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/7544674/pubmed\" target=\"_blank\" id=\"7544674\">7544674</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Meyer-Massetti C, Cheng CM, Sharpe BA, Meier CR, Guglielmo BJ. The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond? <i>J Hosp Med</i>. 2010;5(4):E8-E16.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/20394022/pubmed\" target=\"_blank\" id=\"20394022\">20394022</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mitchell PB. Therapeutic drug monitoring of psychotropic medications. <i>Br J Clin Pharmacol</i>. 2001;(52)(Suppl 1):45S-54S.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/11564052/pubmed\" target=\"_blank\" id=\"11564052\">11564052</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Collaborating Centre for Mental Health; National Institute for Health and Care Excellence. Violence and aggression: short-term management in mental health, health and community settings: updated edition. London, UK: British Psychological Society; 2015. https://www.nice.org.uk/guidance/ng10/resources/violence-and-aggression-shortterm-management-in-mental-health-health-and-community-settings-1837264712389. Accessed August 14, 2015.26180871</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Newport DJ, Calamaras MR, DeVane CL, et al, &ldquo;Atypical Antipsychotic Administration During Late Pregnancy: Placental Passage and Obstetrical Outcomes,&rdquo; <i>Am J Psychiatry</i>, 2007, 164(8):1214-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/17671284/pubmed\" target=\"_blank\" id=\"17671284\">17671284</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"28758203\"></a>Ostinelli EG, Brooke-Powney MJ, Li X, et al. Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation). <i>Cochrane Database Syst Rev.</i> 2017;7:CD009377. doi: 10.1002/14651858.CD009377.pub3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/28758203/pubmed\" target=\"_blank\" id=\"28758203\">28758203</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pringsheim T, Doja A, Gorman D, et al. Canadian guidelines for the evidence-based treatment of tic disorders: pharmacotherapy. <i>Can J Psychiatry</i>. 2012;57(3):133-143.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/22397999/pubmed\" target=\"_blank\" id=\"22397999\">22397999</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reade MC, O&rsquo;Sullivan K, Bates S, et al, &ldquo;Dexmedetomidine vs Haloperidol in Delirious, Agitate, Intubated Patients: A Randomized Open-Label Trial,&rdquo; <i>Crit Care</i>, 2009, 13(3):R75.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/19454032/pubmed\" target=\"_blank\" id=\"19454032\">19454032</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Remington G, Chue P, Stip E, Kopala L, Girard T, Christensen B. The crossover approach to switching antipsychotics: what is the evidence? <i>Schizophr Res</i>. 2005;76(2-3):267-272. doi: 10.1016/j.schres.2005.01.009.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/15949658/pubmed\" target=\"_blank\" id=\"15949658\">15949658</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reilmann R. Pharmacological treatment of chorea of Huntington's disease&mdash;good clinical practice versus evidence-based guideline. <i>Mov Disord</i>. 2013;28(8):1030-1033.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/23674480/pubmed\" target=\"_blank\" id=\"23674480\">23674480</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reus VI, Fochtmann LJ, Eyler AE, et al. The American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. Am J Psychiatry. 2016;173(5):543-546. http://ajp.psychiatryonline.org/doi/pdf/10.1176/appi.ajp.2015.173501. Accessed May 26, 2016. doi: 10.1176/appi.ajp.2015.173501.27133416</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Richelson E. Receptor pharmacology of neuroleptics: relation to clinical effects. <i>J Clin Psychiatry</i>. 1999;60 suppl 10:5-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/10340682/pubmed\" target=\"_blank\" id=\"10340682\">10340682</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Risch SC. Pathophysiology of schizophrenia and the role of newer antipsychotics. <i>Pharmacotherapy</i>. 1996;16(1 pt 2):11-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/8778681/pubmed\" target=\"_blank\" id=\"8778681\">8778681</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roessner V, Plessen KJ, Rothenberger A, et al; ESSTS Guidelines Group. European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment [published correction appears in <i>Eur Child Adolesc Psychiatry</i>. 2011;20(7):377]. <i>Eur Child Adolesc Psychiatry</i>. 2011;20(4):173-196.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/21445724/pubmed\" target=\"_blank\" id=\"21445724\">21445724</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roila F, Molassiotis A, Herrstedt J, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. <i>Ann Oncol</i>. 2016;27(suppl 5):v119-v133.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/27664248/pubmed\" target=\"_blank\" id=\"27664248\">27664248</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sassa T, Suhara T, Ikehira H, et al. 19F-magnetic resonance spectroscopy and chemical shift imaging for schizophrenic patients using haloperidol decanoate. <i>Psychiatry Clin Neurosci</i>. 2002;56(6):637-642.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/12485307/pubmed\" target=\"_blank\" id=\"12485307\">12485307</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Scahill L, Erenberg G, Berlin CM Jr, et al; Tourette Syndrome Association Medical Advisory Board: Practice Committee. Contemporary assessment and pharmacotherapy of Tourette syndrome. <i>NeuroRx</i>. 2006;3(2):192-206.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/16554257/pubmed\" target=\"_blank\" id=\"16554257\">16554257</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"1970586\"></a>Schneider LS, Pollock VE, Lyness SA. A metaanalysis of controlled trials of neuroleptic treatment in dementia. <i>J Am Geriatr Soc</i>. 1990;38(5):553-563.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/1970586/pubmed\" target=\"_blank\" id=\"1970586\">1970586</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Soares-Weiser K, Fernandez HH. Tardive dyskinesia. <i>Semin Neurol</i>. 2007;27(2):159-169.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/17390261/pubmed\" target=\"_blank\" id=\"17390261\">17390261</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Strawn JR, Keck PE Jr, Caroff SN. Neuroleptic malignant syndrome. <i>Am J Psychiatry</i>. 2007;164(6):870-876.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/17541044/pubmed\" target=\"_blank\" id=\"17541044\">17541044</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"Tesar.1988\"></a>Tesar GE and Stern TA, &ldquo;Analytic Reviews: Rapid Tranquilization of the Agitated Intensive Care Unit Patient,&rdquo; <i>J Intensive Care Med</i>, 1988, 3(4):195-201.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Teva-Haloperidol (haloperidol) [product monograph]. Toronto, Ontario, Canada: Teva Canada Limited; August 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Walsh D, Davis M, Ripamonti C, et al. 2016 Updated MASCC/ESMO consensus recommendations: Management of nausea and vomiting in advanced cancer<i>. Support Care Cancer.</i> 2017;25(1):333-340.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/27534961/pubmed\" target=\"_blank\" id=\"27534961\">27534961</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Whalley LJ, Blain PG, and Prime JK, &ldquo;Haloperidol Secreted in Breast Milk,&rdquo; <i>Br Med J (Clin Res Ed)</i>, 1981, 282(6278):1746-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/6786603/pubmed\" target=\"_blank\" id=\"6786603\">6786603</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Willner MM, Gordon LE. Psychotropic drugs in children. Pharmacotherapy as an adjunct to counseling or psychotherapy. <i>Clin Pediatr (Phila)</i>. 1969;8(4):193-200.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/4887476/pubmed\" target=\"_blank\" id=\"4887476\">4887476</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21601409\"></a>Wilson MP, MacDonald K, Vilke GM, Feifel D. A comparison of the safety of olanzapine and haloperidol in combination with benzodiazepines in emergency department patients with acute agitation. <i>J Emerg Med</i>. 2012;43(5):790-797.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/21601409/pubmed\" target=\"_blank\" id=\"21601409\">21601409</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yasuhara Y, Hirai E, Sakamaki S, et al. Using ultrasonography in the intramuscular injection techniques used for administering drug treatments to schizophrenic patients in Japan. <i>J Med Invest</i>. 2012;59(1-2):213-219.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/22450010/pubmed\" target=\"_blank\" id=\"22450010\">22450010</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yoshida K, Smith B, and Kumar R, &ldquo;Psychotropic Drugs in Mothers' Milk: A Comprehensive Review of Assay Methods, Pharmacokinetics and of Safety of Breast-Feeding,&rdquo; <i>J Psychopharmacol</i>, 1999, 13(1):64-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/10221361/pubmed\" target=\"_blank\" id=\"10221361\">10221361</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8516 Version 261.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F6697563\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F178552\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F178553\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F178603\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F178557\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F178580\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F178558\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F178559\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15897441\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F178524\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F178509\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F178529\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F178528\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25474798\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F178612\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F178516\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F178532\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F178513\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F178598\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F178518\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F178520\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F10869024\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F178535\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F178522\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F178525\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F178512\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F178531\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F178534\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F178536\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8516|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=haloperidol-patient-drug-information\" class=\"drug drug_patient\">Haloperidol: Patient drug information</a></li><li><a href=\"topic.htm?path=haloperidol-pediatric-drug-information\" class=\"drug drug_pediatric\">Haloperidol: Pediatric drug information</a></li></ul></div></div>","javascript":null}